创新医疗(002173) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥171,290,921.92, representing a 6.13% increase compared to ¥161,392,113.23 in the same period last year[4] - The net profit attributable to shareholders was -¥14,238,149.54, an improvement of 40.81% from -¥24,053,643.08 year-on-year[4] - The company's basic earnings per share were -¥0.03, improving by 40.00% from -¥0.05 in the same period last year[4] - The weighted average return on equity was -0.72%, an improvement of 0.42% from -1.14% year-on-year[4] - Total operating revenue for Q1 2022 was CNY 171,290,921.92, an increase of 6.4% compared to CNY 161,392,113.23 in Q1 2021[19] - Net loss for Q1 2022 was CNY 14,211,186.74, an improvement from a net loss of CNY 24,022,128.39 in Q1 2021[20] - The company reported a gross profit margin of approximately -10.5% for Q1 2022, compared to -8.5% in Q1 2021[20] - Basic and diluted earnings per share for Q1 2022 were both negative CNY 0.03, an improvement from negative CNY 0.05 in Q1 2021[20] Cash Flow and Operating Activities - The net cash flow from operating activities was -¥72,743,214.00, a significant decline of 635.64% compared to -¥9,888,396.53 in the previous year[4] - The company experienced a 73.60% decrease in cash received from operating activities, totaling ¥3,926,240.98 compared to ¥14,873,610.04 in the previous year[10] - Operating cash flow for Q1 2022 was negative CNY 72,743,214.00, compared to negative CNY 9,888,396.53 in the same period last year[23] - Cash and cash equivalents at the end of Q1 2022 totaled CNY 132,404,379.55, down from CNY 276,245,532.99 at the end of Q1 2021[24] - The company's cash and cash equivalents decreased from ¥225,710,845.59 to ¥132,404,379.55, a decline of about 41.29%[15] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,445,530,025.68, down 4.33% from ¥2,556,184,699.61 at the end of the previous year[4] - The company's total assets at the end of the reporting period amount to ¥2,445,530,025.68, down from ¥2,556,184,699.61 at the beginning of the year, representing a decrease of approximately 4.34%[16] - Total current assets decreased from ¥940,020,380.04 to ¥845,644,918.27, a decline of about 10.03%[16] - Total current liabilities decreased from ¥345,968,853.24 to ¥283,117,970.20, a reduction of approximately 18.14%[17] - The company has a total liability of ¥468,824,977.29, down from ¥565,268,463.48, indicating a decrease of approximately 17.14%[17] - The company's total liabilities decreased by 24.59% to ¥98,345,176.53, primarily due to repayments of long-term borrowings[10] Shareholder Information - The total number of common shareholders at the end of the reporting period is 41,312, with no preferred shareholders having restored voting rights[12] - The largest shareholder, Chen Xiaying, holds 17.13% of shares, amounting to 77,616,997 shares, with 37,700,000 shares pledged[12] Expenses and Other Income - The company reported a significant increase in sales expenses, which rose by 99.34% to ¥2,218,957.65 due to increased marketing efforts in its subsidiary[10] - Other income increased by 260.49% to ¥1,002,214.14, primarily due to increased government subsidies received[10] - Total operating costs for Q1 2022 were CNY 190,078,948.39, up 4.5% from CNY 182,033,255.24 in the previous year[19] - The company incurred research and development expenses, although specific figures were not disclosed in the report[19] Future Plans and Audit Status - The company plans to focus on market expansion and new product development in the upcoming quarters[20] - The report was not audited, indicating that the figures may be subject to change upon further review[25]